NMDA channel blockers: memantine and amino-aklylcyclohexanes--in vivo characterization.
The previous overviews provided the basis for better therapeutic efficacy/tolerability of low to moderate affinity NMDA channel blockers. This prediction finds support in in vitro studies comparing protective and plasticity impairing effects (therapeutic vs. side-effect) of memantine and (+)MK-801. In fact it turned out that memantine had a far better therapeutic index. But can it be confirmed in the in vivo situation?
Danysz
W
W
Department of Pharmacological Research, Merz+Co, Frankfurt/Main, Federal Republic of Germany.
Parsons
C G
CG
Quack
G
G
D000818:Animals; D003510:Cyclohexanes / Q000494:pharmacology*; D018691:Excitatory Amino Acid Antagonists / Q000494:pharmacology*; D008559:Memantine / Q000494:pharmacology*; D016194:Receptors, N-Methyl-D-Aspartate / Q000037:antagonists & inhibitors*
D003510:Cyclohexanes; D018691:Excitatory Amino Acid Antagonists; D016194:Receptors, N-Methyl-D-Aspartate; D008559:Memantine